Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Dose Escalation, Dose Expansion, and Dose Optimization Study of the Safety, Tolerability, and Anti-tumor Activity of SAR444881 Administered Alone and in Combination With Pembrolizumab, Cetuximab and/or Chemotherapy in Participants With Advanced Solid Tumors

NCT04717375 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT04717375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04717375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Dose Escalation, Dose Expansion, and Dose Optimization Study of the Safety, Tolerability, and Anti-tumor Activity of SAR444881 Administered Alone and in Combination With Pembrolizumab, Cetuximab and/or Chemotherapy in Participants With Advanced Solid Tumors
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Terminated
Start date
April 11, 2021
Completion date
July 2, 2025
Enrollment
125 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, neoplasm